2022
Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study.
Gubitosi-Klug RA, Braffett BH, Bebu I, Johnson ML, Farrell K, Kenny D, Trapani VR, Meadema-Mayer L, Soliman EZ, Pop-Busui R, Lachin JM, Bergenstal RM, Tamborlane WV. Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. Diabetes Care 2022, 45: 659-665. PMID: 35076697, PMCID: PMC8918229, DOI: 10.2337/dc21-0629.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringInsulin pumpDCCT/EDIC studyComplications Trial/EpidemiologyGlucose monitoringPercent timeRelevant clinical goalsYears of ageMean sensor glucoseSubset of adultsComplications StudyEDIC studyEntire recording periodOlder patientsGlycemic excursionsDiabetes controlSignificant hypoglycemiaDiabetes InterventionsYears durationHypoglycemiaSensor glucoseClinical goalsHyperglycemic excursionsType 1
2016
Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide
Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.Peer-Reviewed Original ResearchConceptsAdjunctive agentsInsulin deliveryTotal daily insulin doseWeight lossDose escalation periodClosed-loop insulin deliveryDaily insulin dosePlasma glucose excursionsLoop insulin deliveryPrandial insulin deliveryContent of mealsConcomitant bluntingLiraglutide therapyDose titrationLiraglutide treatmentDose escalationInsulin doseGlycemic excursionsGlucose excursionsPostprandial hyperglycemiaPostprandial incrementLiraglutidePramlintideBeneficial effectsEscalation period
2014
Persistently high glucose levels in young children with type 1 diabetes
Tansey M, Beck R, Ruedy K, Tamborlane W, Cheng P, Kollman C, Fox L, Weinzimer S, Mauras N, White N, Tsalikian E, Network F. Persistently high glucose levels in young children with type 1 diabetes. Pediatric Diabetes 2014, 17: 93-100. PMID: 25496062, PMCID: PMC4465416, DOI: 10.1111/pedi.12248.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose levelsMin/dContinuous glucose monitorGlycemic excursionsYoung childrenPostprandial glycemic excursionsSuboptimal glycemic controlPercent of participantsHigh glucose levelsOverall mean glucoseMean hemoglobinGlycemic targetsGlycemic controlMedian timeMean glucoseCGM metricsNormal rangeAge groupsT1DHyperglycemic rangeValue 71Age rangeCGM dataAge 8
2012
Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes
Weinzimer SA, Sherr JL, Cengiz E, Kim G, Ruiz JL, Carria L, Voskanyan G, Roy A, Tamborlane WV. Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes. Diabetes Care 2012, 35: 1994-1999. PMID: 22815298, PMCID: PMC3447854, DOI: 10.2337/dc12-0330.Peer-Reviewed Original ResearchConceptsGlycemic excursionsBG excursionsEffects of pramlintideBlood glucose excursionsAbsorption of insulinContent of mealsPreprandial injectionsInsulin levelsPostprandial glycemiaGlucose excursionsInsulin delivery systemsInsulin concentrationsGlucose riseManual bolusesInsulin feedbackPostprandial BGStudy daysPramlintideCL controlInsulin absorptionType 1Beneficial effectsSubcutaneous sitesTarget glucoseYoung adults
2011
Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study
Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV. Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatric Diabetes 2011, 13: 6-11. PMID: 21722284, DOI: 10.1111/j.1399-5448.2011.00793.x.Peer-Reviewed Original ResearchConceptsType 1 diabetesSensor-augmented pump therapyA1C valuesSAP groupMDI groupPump therapyA1C targetsSAP therapyHyperglycemic excursionsMultiple daily injection therapyBaseline A1C valuesRisk of hypoglycemiaA1C reductionInjection therapyPediatric patientsGlycemic excursionsGlucose variabilityMDI therapyGlycemic variabilityLower AUC valuesTreatment groupsTherapyCGM studiesDiabetesAUC values
2008
Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV, . Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2008, 32: 387-393. PMID: 19106380, PMCID: PMC2646014, DOI: 10.2337/dc08-0800.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsInsulin glargineType 1 diabetesGlucose variabilityLente insulinPediatric patientsDaily injectionsBasal insulin componentOpen-label studySubset of patientsContinuous glucose monitoring systemMDI regimenGlucose monitoring systemGlycemic excursionsInsulin componentInsulin lisproContinuous glucose monitoring dataGlargineGlucose valuesGlucose monitoring dataType 1PatientsInsulinGreater reductionDiabetesFully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas
Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Diabetes Care 2008, 31: 934-939. PMID: 18252903, DOI: 10.2337/dc07-1967.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose levelsHCl groupFCL groupInsulin pumpBeta cell replacement therapyPostprandial glycemic excursionsPostprandial glucose excursionsPostprandial glucose levelsClosed-loop glucose controlArtificial pancreasClosed-loop artificial pancreasPediatric patientsPostprandial excursionsBolus dosesGlycemic excursionsReplacement therapySubcutaneous routeGlucose controlGlucose excursionsInsulin delivery systemsHybrid closed-loop controlInsulin absorptionType 1Dl